Corteva Inc. (CTVA) had a rough Thursday morning. The agricultural chemicals company reported weaker-than-expected third-quarter results and cut its 2026 forecast, sending shares down 7.66% to $11.21 in premarket trading. That's a new 52-week low, according to market data.

The headline numbers were not pretty. Corteva reported adjusted pro forma operating earnings of 6 cents per share, missing the 10-cent consensus estimate. Sales fell 9% to $1.59 billion from $1.742 billion a year earlier, missing Wall Street's $1.764 billion estimate.

On a GAAP basis, the company reported a loss from continuing operations of 8 cents per share, compared with earnings of 9 cents a year earlier. Adjusted pro forma operating EBITDA declined 17% to $222 million, and the margin narrowed 140 basis points to 14%.

Pricing Pressure Hits Profitability

Organic sales fell 9%, reflecting a 2% decline in volume and a 7% drop in pricing. About 90% of the pricing pressure came from U.S. acetochlor products and Latin America. That's a concentrated pain point, not a broad-based collapse.

There was a silver lining: new-product volume rose 20% across all regions, led by Arylex. So the innovation pipeline is working, even if the legacy portfolio is taking a beating.

Brazil Weakness Weighs on Sales

Latin America organic sales plunged 31% as elevated inventories and delayed purchases hurt demand in Brazil. Farmer liquidity constraints and high interest rates added pressure. CEO Luke Kissam said Brazil was "materially weaker than anticipated," even as new products performed strongly and organic sales grew across regions outside Latin America. He emphasized that Corteva remains committed to its growth strategy despite the challenging market conditions.

The regional picture was mixed. North America organic sales rose 7%, supported by 19% volume growth. Europe, the Middle East and Africa gained 14%, while Asia Pacific increased 5%. So outside Brazil, the business is actually growing.

By product category, herbicide sales fell 10%, insecticides declined 3%, fungicides dropped 23%, and biologicals decreased 22%. Cost savings and lower administrative expenses partly offset pricing pressure, but higher research and development spending weighed on profitability. Corteva ended September with $1.798 billion in cash and cash equivalents.

Corteva Slashes 2026 Forecast

Corteva lowered its full-year adjusted pro forma operating earnings forecast to 76 cents to 80 cents per share, below the $1.07 analyst estimate. The company also expects adjusted pro forma operating EBITDA of $1.1 billion to $1.125 billion.

Meanwhile, Corteva expects $130 million to $140 million in pretax restructuring charges in 2026 as it streamlines its Crop Protection operations. The company expects to substantially complete the restructuring by 2028.

For investors, the question is whether Brazil is a temporary hiccup or a longer-term problem. Kissam's comments suggest the company sees it as the former, but the market is clearly pricing in some skepticism. The stock's slide to a 52-week low tells you all you need to know about sentiment right now.